Physician profile
Marvin Ament
NPI 1962447896
$816.38
in general payments reported to CMS, 2019-2025
17 companies · $37.73 in 2025
The $37.73 reported for 2025 was less than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.09 · 2020: $90.52 · 2021: $17.09 · 2022: $81.79 · 2023: $139 · 2024: $403 · 2025: $37.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $318 · Education: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $318.33 |
| Education | $261.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $273.13 | 2022-2024 | Ensite |
| Genzyme Corporation | $86.46 | 2022-2023 | |
| Abbvie INC. | $57.99 | 2020-2021 | |
| Rhythm Pharmaceuticals, INC. | $50.43 | 2023-2024 | Imcivree, Imcivree |
| Pfizer INC. | $47.12 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $45.93 | 2023-2024 | Dupixent |
| Mirum Pharmaceuticals, INC. | $45.61 | 2022-2024 | Livmarli |
| Qol Medical, LLC | $40.90 | 2020-2024 | Sucraid |
| Acadia Pharmaceuticals INC | $27.82 | 2024 | Daybue |
| Kyowa Kirin, INC. | $23.94 | 2023 | Crysvita |
| Ucb, INC. | $20.15 | 2025 | Briviact |
| Takeda Pharmaceuticals U.S.A., INC. | $17.90 | 2024 | Eohilia |
| Xeris Pharmaceuticals, INC. | $17.58 | 2025 | Gvoke Hypopen |
| Boston Scientific Corporation | $16.99 | 2020 | |
| Ascendis Pharma Endocrinology INC | $15.53 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $14.72 | 2019 | |
| Janssen Biotech, INC. | $14.18 | 2023 | Stelara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Ament listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.